PT  - JOURNAL ARTICLE
AU  - van Gils, Marit J.
AU  - Lavell, A. H. Ayesha
AU  - van der Straten, Karlijn
AU  - Appelman, Brent
AU  - Bontjer, Ilja
AU  - Poniman, Meliawati
AU  - Burger, Judith A.
AU  - Oomen, Melissa
AU  - Bouhuijs, Joey H.
AU  - van Vught, Lonneke A.
AU  - Slim, Marleen A.
AU  - Schinkel, Michiel
AU  - Wynberg, Elke
AU  - van Willigen, Hugo D.G.
AU  - Grobben, Marloes
AU  - Tejjani, Khadija
AU  - Snitselaar, Jonne
AU  - Caniels, Tom G.
AU  - ,
AU  - Vlaar, Alexander P. J.
AU  - Prins, Maria
AU  - de Jong, Menno D.
AU  - de Bree, Godelieve J.
AU  - Sikkens, Jonne J.
AU  - Bomers, Marije K.
AU  - Sanders, Rogier W.
TI  - Four SARS-CoV-2 vaccines induce quantitatively different antibody responses against SARS-CoV-2 variants
AID  - 10.1101/2021.09.27.21264163
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.27.21264163
4099  - http://medrxiv.org/content/early/2021/09/28/2021.09.27.21264163.short
4100  - http://medrxiv.org/content/early/2021/09/28/2021.09.27.21264163.full
AB  - Emerging and future SARS-CoV-2 variants may jeopardize the effectiveness of vaccination campaigns. We performed a head-to-head comparison of the ability of sera from individuals vaccinated with either one of four vaccines (BNT162b2, mRNA-1273, AZD1222 or Ad26.COV2.S) to recognize and neutralize the four SARS-CoV-2 variants of concern (VOCs; Alpha, Beta, Gamma and Delta). Four weeks after completing the vaccination series, SARS-CoV-2 wild-type neutralizing antibody titers were highest in recipients of BNT162b2 and mRNA-1273 (median titers of 1891 and 3061, respectively), and substantially lower in those vaccinated with the adenovirus vector-based vaccines AZD1222 and Ad26.COV2.S (median titers of 241 and 119, respectively). VOCs neutralization was reduced in all vaccine groups, with the largest (5.8-fold) reduction in neutralization being observed against the Beta variant. Overall, the mRNA vaccines appear superior to adenovirus vector-based vaccines in inducing neutralizing antibodies against VOCs four weeks after the final vaccination.Competing Interest StatementThe authors have declared no competing interest.Funding Statementthe Netherlands Organization for Scientific Research (NWO) ZonMw (no. 10430022010023 no. 10150062010002 no. 91818627) the Bill & Melinda Gates Foundation (no. INV-002022 no. INV008818 no. INV-024617) the Amsterdam UMC through the AMC Fellowship and the Corona Research Fund the European Unions Horizon 2020 program (no. 101003589).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The S3 study, the COSCA study and the RECoVERED study were approved by the medical ethical review board of the Amsterdam University Medical Centers (NL73478.029.20, NL73281.018.20 and NL73759.018.20, respectively). All participants provided written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the main text or supplementary materials. Reagents used in this study are available upon reasonable request under an MTA with Amsterdam UMC.